These shared mechanisms suggest opportunities for cross-cancer therapeutic strategies, with the PI3K/mTOR pathway already showing promise through inhibitors such as BKM120 and BYL719, which act as radiosensitizers in OSCC (32). Here, MTOR is linked to cancer.